[ATRA] Atara Biotherapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 622.51 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.65 Change: 1.15 (7.93%)
Ext. hours: Change: 0 (0%)

chart ATRA

Refresh chart

Description: Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.74 M EPS-3.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.18
P/E To EPS Growth P/S P/BV3.75 Price/Cash Per Share3.73
Price/Free Cash Flow-37.33 ROA-17.74% ROE-18.13% ROI
Current Ratio48.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities69.49 M Cash From Investing Activities-13.43 M Cash From Operating Activities-6.62 M Gross Profit
Net Profit-9.16 M Operating Profit-9.31 M Total Assets169.82 M Total Current Assets169.69 M
Total Current Liabilities3.51 M Total Debt Total Liabilities3.72 M Total Revenue
Technical Data
High 52 week46.05 Low 52 week23.99 Last close23.99 Last change-0.74%
RSI24.66 Average true range2.16 Beta1.91 Volume116.19 K
Simple moving average 20 days-21.91% Simple moving average 50 days-31.48% Simple moving average 200 days-35.01%
Performance Data
Performance Week-7.73% Performance Month-26.37% Performance Quart-40.69% Performance Half-30.98%
Performance Year-45.66% Performance Year-to-date-30.94% Volatility daily5.98% Volatility weekly13.37%
Volatility monthly27.4% Volatility yearly94.93% Relative Volume166.51% Average Volume589.17 K
New High New Low

News

2019-09-13 07:40:02 | The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

2019-09-13 06:15:00 | Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

2019-09-12 18:21:27 | 3 Small-Cap Stock Picks From Seth Klarman

2019-09-10 13:58:55 | Baupost's Seth Klarman Dives Further Into Translate Bio

2019-09-09 08:00:00 | Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

2019-08-28 16:05:00 | Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

2019-08-28 10:02:02 | Are Options Traders Betting on a Big Move in Atara ATRA Stock?

2019-08-12 14:27:33 | Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT

2019-08-08 14:43:07 | Atara Biotherapeutics, Inc. ATRA Q2 2019 Earnings Call Transcript

2019-08-08 07:30:00 | Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress

2019-08-05 14:08:49 | Analysts Recommend These 2 Falling Knives

2019-08-01 16:00:00 | Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019

2019-07-18 23:52:04 | Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering

2019-07-18 16:01:00 | Atara Biotherapeutics Announces Proposed Offering of Common Stock

2019-07-16 07:00:00 | Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year

2019-07-09 13:58:30 | 5 Immunotherapy Stocks to Keep a Close Eye On

2019-07-09 08:00:00 | Why Atara Biotherapeutics Has Slumped in 2019

2019-07-01 09:25:01 | Atara Reports Initial Data for Multiple Sclerosis Candidate

2019-06-29 07:00:00 | Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology EAN

2019-06-25 16:05:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-23 15:52:49 | Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc ATRA ?

2019-06-05 16:30:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635C4

2019-06-04 09:36:00 | Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

2019-06-03 11:00:00 | Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO

2019-06-01 09:00:00 | Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology ASCO Annual Meeting

2019-05-30 17:38:16 | Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

2019-05-28 17:00:00 | Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors

2019-05-15 17:05:00 | Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology ASCO Annual Meeting

2019-05-15 08:30:00 | Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology EAN

2019-05-10 09:29:57 | Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT

2019-05-09 15:25:00 | Why Atara Biotherapeutics Stock Is Imploding Today

2019-05-09 08:19:32 | Atara Biotherapeutics: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress

2019-05-09 06:30:00 | Atara Biotherapeutics, Inc. to Host Earnings Call

2019-05-07 16:41:24 | Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

2019-05-07 09:00:00 | Where Will Gilead Sciences Spend Its Cash?

2019-05-02 12:42:54 | Here is What Hedge Funds Think About Atara Biotherapeutics Inc ATRA

2019-04-23 08:44:00 | 2 Best Biotech Buyout Plays

2019-04-01 16:10:00 | Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research AACR Annual Meeting 2019

2019-03-31 11:00:00 | Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

2019-03-08 13:55:07 | The Atara Biotherapeutics NASDAQ:ATRA Share Price Has Gained 122%, So Why Not Pay It Some Attention?

2019-03-07 09:00:00 | Atara Biotherapeutics to Participate in Upcoming Conferences

2019-03-06 17:20:40 | How attacking a virus in cancer patients helped a Peninsula company target MS

2019-02-27 17:20:00 | Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research AACR Annual Meeting 2019

2019-02-26 07:30:00 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress

2019-02-13 08:00:00 | Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group — Fundamental Analysis, Key Performance Indications

2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

2019-01-04 16:05:00 | Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference

2019-01-04 10:01:03 | Company News For Jan 4, 2019

2019-01-03 16:32:00 | Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today